small molecule

VIGABATRIN

VIGABATRIN

Loss of exclusivityloss of exclusivity
CompanyDEXCEL PHARMA TECHNOLOGIES LTD

Drug detail

Brand nameVIGABATRIN
Active ingredientVIGABATRIN
Strength500MG/PACKET
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2021
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VIGABATRIN patent cliff — loss of exclusivity — | CliffBio